GSK has spent slightly more on lobbying this year compared with 2023. The company spent $3.87 million in the first three ...

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

The U.S. Food and Drug Administration has proposed removing oral phenylephrine, widely used in cold and cough syrups, as an active ingredient ... ingredient Companies such as Procter & Gamble and GSK ...

It would be unhealthy to let Robert F. Kennedy Jr. take charge of U.S. physical well-being. President-elect Donald Trump said on the campaign trail that he wants the anti-vaccine activist to “run wild ...

The US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups.

WASHINGTON — Pharmaceutical industry giant GSK plans to depart the biotechnology industry’s largest trade group, the ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax ...

Syndax Pharmaceuticals and Royalty Pharma plc today announced that Syndax has entered into a $350 million synthetic royalty funding agreement with Royalty Pharma based on U.S. net sales ...

The investigational new drug application is sponsored by GSK, which is codeveloping the drug with Ideaya. The companies plan to evaluate IDE275, also called GSK959, as both a monotherapy agent and in ...

GSK (GSK) plc announced what it calls its “largest U.S. manufacturing investment to date.” The up to $800M investment will bring state-of-the-art drug substance manufacturing and additional ...